Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Tandem Meetings 2023 | Real-world study of tixagevimab/cilgavimab in pre-exposure prophylaxis for alloSCT recipients

Jaime Shahan • 17 Feb 2023
Tandem Meetings 2023
General Antibodies Cilgavimab Tixagevimab

Jaime Shahan, MPAS, PA-C, UT Southwestern Medical Center, Dallas, TX, comments on the results of a real-world study assessing the efficacy and safety of tixagevimab/cilgavimab (Txg/Cgv; Evusheld™) as pre-exposure prophylaxis in allogeneic stem cell transplant (alloSCT) recipients. Out of 18 patients who received Txg/Cgv, two developed COVID-19 and one required hospitalization. In addition, although two patients developed new onset graft-versus-host disease (GvHD) and two had progressive GvHD, further studies must be conducted to confirm whether this is associated with the use of Txg/Cgv. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals